These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 22727389)

  • 1. Management strategies for relapsed/refractory multiple myeloma: current clinical perspectives.
    Jakubowiak A
    Semin Hematol; 2012 Jul; 49 Suppl 1():S16-32. PubMed ID: 22727389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The future of therapy for relapsed/refractory multiple myeloma: emerging agents and novel treatment strategies.
    Moreau P
    Semin Hematol; 2012 Jul; 49 Suppl 1():S33-46. PubMed ID: 22727391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Choosing treatment options for patients with relapsed/refractory multiple myeloma.
    Castelli R; Orofino N; Losurdo A; Gualtierotti R; Cugno M
    Expert Rev Anticancer Ther; 2014 Feb; 14(2):199-215. PubMed ID: 24329153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of relapsed and refractory multiple myeloma in the era of novel agents.
    van de Donk NW; Lokhorst HM; Dimopoulos M; Cavo M; Morgan G; Einsele H; Kropff M; Schey S; Avet-Loiseau H; Ludwig H; Goldschmidt H; Sonneveld P; Johnsen HE; Bladé J; San-Miguel JF; Palumbo A
    Cancer Treat Rev; 2011 Jun; 37(4):266-83. PubMed ID: 20863623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
    Richardson P
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib: a valuable new antineoplastic strategy in multiple myeloma.
    Bladé J; Cibeira MT; Rosiñol L
    Acta Oncol; 2005; 44(5):440-8. PubMed ID: 16118077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of relapsed/refractory multiple myeloma.
    Kastritis E; Palumbo A; Dimopoulos MA
    Semin Hematol; 2009 Apr; 46(2):143-57. PubMed ID: 19389498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of multiple myeloma with bortezomib: experts review the data and debate the issues.
    Dicato M; Boccadoro M; Cavenagh J; Harousseau JL; Ludwig H; San Miguel J; Sonneveld P
    Oncology; 2006; 70(6):474-82. PubMed ID: 17283449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and 'retreatment' approaches in the era of novel agents.
    Mohty B; El-Cheikh J; Yakoub-Agha I; Avet-Loiseau H; Moreau P; Mohty M
    Leukemia; 2012 Jan; 26(1):73-85. PubMed ID: 22024721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relapsed/Refractory multiple myeloma: defining refractory disease and identifying strategies to overcome resistance.
    Siegel DS
    Semin Hematol; 2012 Jul; 49 Suppl 1():S3-15. PubMed ID: 22727390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical roundtable monograph. Emerging treatment options for relapsed and refractory multiple myeloma.
    Siegel DS; Vij R; Jakubowiak AJ
    Clin Adv Hematol Oncol; 2011 Apr; 9(4):1-15. PubMed ID: 21928467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma.
    Richardson P; Jagannath S; Colson K
    Clin Adv Hematol Oncol; 2006 May; 4(5):1; discussion 8; suppl 13. PubMed ID: 16830422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New drugs for myeloma.
    Richardson PG; Mitsiades C; Schlossman R; Munshi N; Anderson K
    Oncologist; 2007 Jun; 12(6):664-89. PubMed ID: 17602058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lenalidomide in multiple myeloma.
    Richardson PG; Mitsiades C; Hideshima T; Anderson KC
    Expert Rev Anticancer Ther; 2006 Aug; 6(8):1165-73. PubMed ID: 16925483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma.
    Raje N; Hideshima T; Anderson KC
    Expert Rev Anticancer Ther; 2006 Sep; 6(9):1239-47. PubMed ID: 17020458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma.
    Jagannath S; Dimopoulos MA; Lonial S
    Leuk Res; 2010 Sep; 34(9):1111-8. PubMed ID: 20472288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients.
    van de Donk NW; Lokhorst HM
    Expert Opin Pharmacother; 2013 Aug; 14(12):1569-73. PubMed ID: 23721099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel agents for relapsed and/or refractory multiple myeloma.
    Thomas SK; Richards TA; Weber DM
    Cancer J; 2009; 15(6):485-93. PubMed ID: 20010168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of relapsed and relapsed refractory myeloma.
    Kastritis E; Mitsiades CS; Dimopoulos MA; Richardson PG
    Hematol Oncol Clin North Am; 2007 Dec; 21(6):1175-215, x. PubMed ID: 17996594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New drugs in multiple myeloma.
    Berenson JR; Yellin O
    Curr Opin Support Palliat Care; 2008 Sep; 2(3):204-10. PubMed ID: 18685422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.